Curated News
By: NewsRamp Editorial Staff
January 30, 2026
Nutriband Advances Abuse-Deterrent Fentanyl Patch Toward FDA Filing
TLDR
- Nutriband's AVERSA FENTANYL development offers investors a competitive edge through extended patent protection to 2046 and strategic partnerships enhancing market exclusivity.
- Nutriband methodically advanced AVERSA FENTANYL through manufacturing scale-up, FDA engagement, patent expansions, and plans for clinical studies leading to an NDA filing.
- Nutriband's abuse-deterrent fentanyl patch technology makes the world better by preventing drug misuse and accidental exposure, improving patient safety and public health.
- Nutriband's AVERSA technology transforms transdermal patches with abuse-deterrent features, offering an interesting innovation in pharmaceutical safety and drug delivery systems.
Impact - Why it Matters
The development of AVERSA™ FENTANYL addresses a critical public health issue: the opioid epidemic, which has caused widespread addiction and fatalities due to the abuse of potent drugs like fentanyl. By incorporating abuse-deterrent technology into a transdermal patch, this innovation could significantly reduce misuse and accidental exposure, potentially saving lives and easing the burden on healthcare systems. For patients with severe pain who legitimately require fentanyl, it offers a safer administration method, while for society, it represents a proactive step in combating drug diversion. The progress toward regulatory approval and extended patent protection also highlights the economic and therapeutic potential, making it relevant for investors, healthcare providers, and communities affected by opioid abuse.
Summary
Nutriband Inc. (NASDAQ: NTRB, NTRBW) has provided a significant update to shareholders following its 2026 Annual Shareholders Meeting held in Orlando, Florida, on January 24, 2026. The company announced the appointment of two new directors, Alessandro Puddu and Viorica Carlig, to its board, signaling a strategic strengthening of its leadership as it advances its flagship product. The core focus remains on the development of AVERSA™ FENTANYL, an abuse-deterrent fentanyl transdermal patch that incorporates Nutriband's proprietary AVERSA™ technology. This technology is designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with high abuse potential, positioning the product as a critical innovation in the ongoing fight against the opioid crisis.
Throughout 2025, Nutriband made substantial progress by strengthening its exclusive partnership with Kindeva, a key player in pharmaceutical development and manufacturing. The company successfully completed commercial manufacturing scale-up for AVERSA™ FENTANYL and expanded its global patent protection, securing new patents in the United States and Macao. Furthermore, Nutriband engaged with the U.S. Food and Drug Administration (FDA) through a Type C meeting, a crucial regulatory step, and advanced its branding initiatives for the product. Looking ahead to 2026, the company has outlined an ambitious roadmap that includes extending patent protection potentially to 2046, manufacturing clinical supplies, filing an Investigational New Drug (IND) application, and initiating a pivotal Human Abuse Liability clinical study, all aimed at advancing toward a New Drug Application (NDA) filing.
This news was disseminated through BioMedWire (“BMW”), a specialized communications platform within the Dynamic Brand Portfolio of IBN (InvestorBrandNetwork), which focuses on the biotechnology and life sciences sectors. BioMedWire provides comprehensive distribution services, including access to wire solutions via InvestorWire, article syndication to over 5,000 outlets, enhanced press release features, and social media distribution through IBN's extensive network. For more detailed information, readers can view the full press release and access the latest updates relating to NTRB in the company’s newsroom. This update underscores Nutriband's commitment to advancing a potentially transformative pharmaceutical product while leveraging robust communication channels to keep investors and the public informed.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband Advances Abuse-Deterrent Fentanyl Patch Toward FDA Filing
